Genmab/Janssen MM drug daratumumab wins 'breakthrough' status
This article was originally published in Scrip
Executive Summary
With only a few revealed early in the year, the breakthrough therapy designations from the FDA are starting to come fast and furious now, with Danish biotech Genmab and its partner Janssen, a subsidiary of Johnson & Johnson, the latest to disclose they'd nabbed the status for their experimental multiple myeloma drug daratumumab.